1. PD-009Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC. (2nd July 2019) Authors: Kaseb, A; Vence, L; Blando, J; Yadav, S; Ikoma, N; Pestana, R; Vauthey, J; Cao, H; Chun, Y; Sakamura, D; Wolff, R; Yao, J; Allison, J; Sharma, P Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗